Cue Biopharma (CUE) Amortization of Deferred Charges (2019 - 2025)

Cue Biopharma has disclosed Amortization of Deferred Charges across 6 years of filings, most recently posting $9000.0 for Q4 2025.

• Amortization of Deferred Charges for Q4 2025 came in at $9000.0, changed 0.0% year-over-year; the trailing twelve-month figure through Dec 2025 was $36000.0 (changed 0.0% YoY), and the FY2025 annual result was $37000.0, changed 0.0% from the prior year.
• Amortization of Deferred Charges came in at $9000.0 for Q4 2025 at Cue Biopharma, roughly flat from $9000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $10000.0 in Q4 2022 to a low of $3000.0 in Q1 2022.
• The 4-year median for Amortization of Deferred Charges is $9000.0 (2022), against an average of $8704.4.
• Peak annual rise in Amortization of Deferred Charges reached 200.0% in 2023, while the deepest fall reached 7.29% in 2023.
• Cue Biopharma's Amortization of Deferred Charges stood at $10000.0 in 2022, then fell by 7.29% to $9271.0 in 2023, then decreased by 2.92% to $9000.0 in 2024, then changed by 0.0% to $9000.0 in 2025.
• The last three Amortization of Deferred Charges figures came in at $9000.0 (Q4 2025), $9000.0 (Q3 2025), and $9000.0 (Q2 2025), per Business Quant data.